Naval G. Daver, MD, on the Past Year in Acute Myeloid Leukemia Research
The leukemia expert offered an overview of agents approved by the FDA this year.
Despite only one new FDA approval in 2020 for treatment of patients with acute myeloid leukemia (AML), tremendous progress was still made.
Several new combination regimens, including venetoclax (Venclexta) and azacitidine (Vidaza) for patients with previously untreated AML, showed positive results and improved outcomes.
In an interview with CancerNetwork®, Naval G. Daver, MD, associate professor in the Department of Leukemia at MD Anderson Cancer Center, discussed the latest advancements in AML and what trial data he is looking forward to most in 2021.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
